Patient and clinical characteristics (N = 72)
| Characteristic . | No. of patients (males/females) . | % . |
|---|---|---|
| Sex | ||
| Male | 41 | 57 |
| Female | 31 | 43 |
| Durie-Salmon classification | ||
| Stage IIA | 32 | 44.4 |
| Stage IIB | 1 | 1.4 |
| Stage IIIA | 36 | 50.0 |
| Stage IIIB | 3 | 4.2 |
| International Staging System classification | ||
| Stage I | 33 | 45.8 |
| Stage II | 26 | 36.1 |
| Stage III | 13 | 18.1 |
| Immunoglobulins, heavy-chain type | ||
| IgA | 16 (7/9) | 22.2 |
| IgG | 44 (28/16) | 61.1 |
| Bence Jones protein | 12 (6/6) | 16.7 |
| Karnofsky performance status | ||
| 90 | 31 | 43.1 |
| 80 | 25 | 34.7 |
| 70 | 12 | 16.7 |
| 60 | 4 | 5.6 |
| Characteristic . | No. of patients (males/females) . | % . |
|---|---|---|
| Sex | ||
| Male | 41 | 57 |
| Female | 31 | 43 |
| Durie-Salmon classification | ||
| Stage IIA | 32 | 44.4 |
| Stage IIB | 1 | 1.4 |
| Stage IIIA | 36 | 50.0 |
| Stage IIIB | 3 | 4.2 |
| International Staging System classification | ||
| Stage I | 33 | 45.8 |
| Stage II | 26 | 36.1 |
| Stage III | 13 | 18.1 |
| Immunoglobulins, heavy-chain type | ||
| IgA | 16 (7/9) | 22.2 |
| IgG | 44 (28/16) | 61.1 |
| Bence Jones protein | 12 (6/6) | 16.7 |
| Karnofsky performance status | ||
| 90 | 31 | 43.1 |
| 80 | 25 | 34.7 |
| 70 | 12 | 16.7 |
| 60 | 4 | 5.6 |
Ig indicates immunoglobulin.